Introduction:
Pfizer, one of the leading global pharmaceutical companies, is launching a call for researchers interested in collaborating on studies of the respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults. The company aims to expand data in severely immunocompromised populations and foster collaboration with research institutions.

General Description:
The call seeks to identify and fund research projects evaluating the immune response of severely immunocompromised adults after vaccination with Abrysvo. Selected researchers will collaborate with Pfizer's medical team to develop the study protocol. The investigator will be the regulatory sponsor of the study.

Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract disease (LRTD) among adults and can lead to serious morbidity and mortality, especially among older adults and adults with underlying comorbidities, such as immunocomprising conditions.

Objectives:

• Assess the immune response to the Abrysvo vaccine in adults ≥18 years old with severe immunocompromising conditions, such as:
  • Hematopoietic stem cell transplant recipients
  • Patients undergoing B-cell depletion therapies
  • Lung transplant recipients
• Develop strategies for recruiting immunocompromised patients for clinical studies
• Define comparison groups and serological sampling strategies for subsequent analysis

The duration of the project is 12 months. 

Eligibility Requirements:

• The institution and Principal Investigator (PI) must be based in an eligible country.
• Only organizations can receive funding and in-kind support; individuals or independent medical practice groups are not eligible.
• If the project involves multiple institutions, all must have a relevant role, with the requesting organization playing a key role.
• The PI must hold a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• The applicant must be the PI or an authorized designee (e.g., PI's research coordinator).
• The PI must be an employee or contractor of the requesting organization.
• If selected, the PI and their organization must be willing to engage in a Research Collaboration with Pfizer.
• In Research Collaborations, the PI is responsible for the project's design, implementation, sponsorship, and regulatory compliance.
• Pfizer may be involved in protocol design and project oversight. Preference will be given to PIs open to collaborative agreements with similar institutions.
• The requesting organization must be legally able to receive funding directly from Pfizer. Applicants should confirm this requirement before applying.

In case of interest, please click on "m'interessa" and we will contact you.